Drug Candidates Debut | Chemical & Engineering News
Volume 90 Issue 16 | p. 42
Issue Date: April 16, 2012

Drug Candidates Debut

ACS Meeting News: Perennial session serves up potential drugs for hepatitis, migraine, cancer, and type 2 diabetes
Department: Science & Technology
Keywords: Medicinal chemistry, organic chemistry, ACS meetings, pharma, biotech, hepatitis, cancer, diabetes, migraine

Medicinal chemists converged on San Diego for this spring’s American Chemical Society national meeting. They packed a ballroom to see the public debut of five drug candidate structures and hear the tales behind their discovery.

The presentations composed the Division of Medicinal Chemistry’s traditional “First Time Disclosures” session, which was supported by Gilead Sciences and organized by Albert J. Robichaud, chief scientific officer of Cambridge, Mass.-based Sage Therapeutics.

“In this time of tumult and uncertainty in the pharmaceutical world it is encouraging to see that scientists and drug discovery groups are still driving value for their organizations,” Robichaud told C&EN. “This session is an excellent example of the quality work that continues to come from the research teams of many of these companies that have experienced significant change.”

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment